인간 마이크로바이옴 시장 보고서 : 제품 유형별, 질환 유형별, 지역별(2024-2032년)

The global human microbiome market size reached US$ 817.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 3,586.3 Million by 2032, exhibiting a growth rate (CAGR) of 17.3% during 2024-2032.

The human microbiome refers to the genes present inside various microorganisms found in the genetic portrait, or metagenome, of humans. It consists of various microorganisms, such as bacteria, fungi, protozoans, non-living viruses and numerous single-celled organisms. These organisms impact human physiology and contribute to the enhancement or impairment of metabolic and immune functions. They are found in the human tissues and are studied for medical advancements and analytical techniques. Microbiomes are utilized in probiotics, prebiotics, pharmaceutical drugs and diagnostic and therapeutic systems for various ailments, such as diabetes, obesity, cancer and metabolic, gastrointestinal, neurological, central nervous system and autoimmune disorders.

Human Microbiome Market Trends:

The increasing prevalence of chronic lifestyle diseases and infections due to microbial dysbiosis across the globe is one of the key factors driving the market growth. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. The growth of the market can also be attributed to the increasing emphasis on the development of human microbiome therapeutics with enhanced efficacy. For instance, human gut microbiomes are being developed in specific combinations for the effective treatment of various gastrointestinal ailments. In line with this, the onset of the coronavirus (COVID-19) pandemic is also providing a thrust to the market growth. Researchers are extensively studying the lung microbiomes to analyze the severity of the infections and develop appropriate therapeutics and vaccines. Additionally, various advancements, such as the development of target-specific microbiome-based therapies, are also favoring the growth of the market. Other factors, including extensive research and development (R&D) activities, along with significant growth in the pharmaceutical industry, especially in the developing economies, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global human microbiome market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, application and disease type.

Breakup by Product:

• Probiotics
• Prebiotics
• Diagnostic Tests
• Drugs
• Medical Food
• Others

Breakup by Application:

• Therapeutics
• Diagnostics

Breakup by Disease Type:

• Obesity
• Diabetes
• Autoimmune Disorders
• Cancer
• Gastrointestinal Disorders
• Central Nervous System Disorders
• Others

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 4D pharma plc, Atlas Biomed Group Limited, BIOHM, BiomX, Bione, DayTwo Inc., ENTEROME, Ferring B.V., Finch Therapeutics, Second Genome Inc., SynBioBeta LLC, Synthetic Biologics Inc., Vedanta Biosciences Inc. and Viome Inc.

Key Questions Answered in This Report:

• How has the global human microbiome market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global human microbiome market?
• What are the key regional markets?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the application?
• What is the breakup of the market based on the disease type?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global human microbiome market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Human Microbiome Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Probiotics
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Prebiotics
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Diagnostic Tests
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Drugs
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Medical Food
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Others
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast

7 Market Breakup by Application

• 7.1 Therapeutics
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Diagnostics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Disease Type

• 8.1 Obesity
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Diabetes
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Autoimmune Disorders
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Cancer
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Gastrointestinal Disorders
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Central Nervous System Disorders
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast
• 8.7 Others
  • 8.7.1 Market Trends
  • 8.7.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 4D pharma plc
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
  • 14.3.2 Atlas Biomed Group Limited
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 BIOHM
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 BiomX
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Bione
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 DayTwo Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 ENTEROME
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Ferring B.V.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Finch Therapeutics
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 Second Genome Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 SynBioBeta LLC
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
  • 14.3.12 Synthetic Biologics Inc.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
  • 14.3.13 Vedanta Biosciences Inc.
    • 14.3.13.1 Company Overview
    • 14.3.13.2 Product Portfolio
  • 14.3.14 Viome Inc.
    • 14.3.14.1 Company Overview
    • 14.3.14.2 Product Portfolio